These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560 [TBL] [Abstract][Full Text] [Related]
3. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. González I; Vicent S; de Alava E; Lecanda F J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169 [TBL] [Abstract][Full Text] [Related]
4. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038 [TBL] [Abstract][Full Text] [Related]
5. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Prieur A; Tirode F; Cohen P; Delattre O Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325 [TBL] [Abstract][Full Text] [Related]
7. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423 [TBL] [Abstract][Full Text] [Related]
8. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061 [TBL] [Abstract][Full Text] [Related]
9. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Yi H; Fujimura Y; Ouchida M; Prasad DD; Rao VN; Reddy ES Oncogene; 1997 Mar; 14(11):1259-68. PubMed ID: 9178886 [TBL] [Abstract][Full Text] [Related]
11. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Chaturvedi A; Hoffman LM; Jensen CC; Lin YC; Grossmann AH; Randall RL; Lessnick SL; Welm AL; Beckerle MC Mol Biol Cell; 2014 Sep; 25(18):2695-709. PubMed ID: 25057021 [TBL] [Abstract][Full Text] [Related]
12. EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model. Peng W; Huang X; Yang D Int Immunopharmacol; 2014 Aug; 21(2):336-41. PubMed ID: 24861249 [TBL] [Abstract][Full Text] [Related]
13. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403 [TBL] [Abstract][Full Text] [Related]
14. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222 [TBL] [Abstract][Full Text] [Related]
15. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Kovar H Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919 [TBL] [Abstract][Full Text] [Related]
16. Detection of EWS/FLI-1 fusion in non-Ewing soft tissue tumors. Trancău IO; Huică R; Surcel M; Munteanu A; Ursaciuc C J Med Life; 2015; 8(1):85-9. PubMed ID: 25914746 [TBL] [Abstract][Full Text] [Related]
17. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma. Huang L; Nakai Y; Kuwahara I; Matsumoto K Cancer Res; 2012 Mar; 72(5):1260-9. PubMed ID: 22241085 [TBL] [Abstract][Full Text] [Related]
18. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Kim S; Denny CT; Wisdom R Mol Cell Biol; 2006 Apr; 26(7):2467-78. PubMed ID: 16537893 [TBL] [Abstract][Full Text] [Related]
19. The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. Hameiri-Grossman M; Porat-Klein A; Yaniv I; Ash S; Cohen IJ; Kodman Y; Haklai R; Elad-Sfadia G; Kloog Y; Chepurko E; Feinmesser M; Issakov J; Sher O; Luria D; Kollender Y; Weizman A; Avigad S Oncotarget; 2015 Oct; 6(32):33834-48. PubMed ID: 26393682 [TBL] [Abstract][Full Text] [Related]
20. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Riggi N; Cironi L; Provero P; Suvà ML; Kaloulis K; Garcia-Echeverria C; Hoffmann F; Trumpp A; Stamenkovic I Cancer Res; 2005 Dec; 65(24):11459-68. PubMed ID: 16357154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]